Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listBilastine

Bilastine

Bilastine Structural

What is Bilastine?

Description

Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ether followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.
In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.

Description

Bilastine is a histamine H1 receptor antagonist (IC50 = 180 nM). It is selective for the histamine H1 receptor in a panel of 30 receptors in vitro at 100 μM. Bilastine prevents microvascular extravasation (ED50 = 185 μg/kg, i.v.), bronchospasm (ED50 = 4.6 μg/kg, i.v.), and systemic anaphylaxis (ED50 = 0.2 μg/kg, p.o.) induced by subcutaneous histamine in guinea pigs. It prevents anaphylaxis induced by subcutaneous administration of ovalbumin or dinitrophenylated human albumin (DNP) in sensitized rats when administered at doses of 7.6 and 6.0 mg/kg, respectively. Formulations containing bilastine have been used in the treatment of urticaria and allergic rhinitis.

Originator

FAES FARMA, S.A. (Spain)

The Uses of Bilastine

Bilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

The Uses of Bilastine

Labelled Bilastine. It is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Background

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

Indications

For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .

Definition

ChEBI: Bilastine is a member of benzimidazoles.

brand name

Bilaxten

Pharmacokinetics

Bilastine is an antiallergenic and acts to reduce allergic symptoms such as nasal congestion and urticaria .

Clinical Use

Bilastine is a selective histamine H1 antagonist approved for the treatment of allergic rhinoconjunctivitis and urticaria (hives). This drug, which has proven to be well tolerated in toxicology profiling, 46 was discovered by the Spainsh firm FAES Farma and was approved by the European Union in 2010.

Synthesis

In 2011, Collier and co-workers published a communication describing both the original synthesis of bilastine and an improved route which was amenable to gram-scale production. Collier?ˉs second generation route, shown below, relies upon a convergent approach involving the union of piperidinyl benzimidazole 49 with fully functionalized phenethyl electrophile 48.Coupling the commercially available bromophenyl acetate 44 with cyclic trioxatriborinane 45 under conventional Suzuki conditions furnished styrene 46 in good yield. Alternatively, this vinylation reaction was also performed under Stille conditions with tributyl vinyl stannane in 83% yield. Hydroboration¨Coxidation of 46 delivered phenethyl alcohol 47 which was then immediately mesylated under basic conditions in toluene to produce adduct 48. This sulfonate was then reacted with piperidine 49 (whose preparation is described in Scheme 7) followed by saponification of the resulting ester 50 to arrive at bilastene (VI) in 26% overall yield from 44.

Synthesis_202189-78-4

For the preparation of bilastine piperidine 49, commercially available piperidine 51 was first protected as the Boc-carbamate 52 prior to alkylation of the benzimidazole nitrogen atom with 1-chloro-2-ethoxyethane 53, providing compound 54. The Boc group of 54 was removed under acidic conditions to give fragment 49. This sequence produced the desired piperidine component in 86% overall yield from 51.
image.png

Drug interactions

Potentially hazardous interactions with other drugs
Antivirals: concentration possibly increased by ritonavir.
Grapefruit juice: concentration of bilastine reduced.

Absorption

Bilastine has a Tmax of 1.13 h . The absolute bioavailability is 61%. No accumulation observed with daily dosing of 20-100 mg after 14 days. Cmax decreased by 25 % and 33% when taken with a low fat and high fat meal compared to fasted state. Administration with grapefruit juice decreased Cmax by 30%.

Metabolism

Bilastine does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans .

Metabolism

Not significantly metabolised. Almost 95% of the administered dose was recovered in urine (28.3%) and faeces (66.5%) as unchanged bilastine

Toxicity

The most common adverse effects experienced during clinical trials were abdominal pain, dizziness, headache, and somnolence . Bilastine is associated with Q/T prolongation. The no observed adverse effect level of bilastine is 1200 mg/kg/day in rats and 125 mg/kg/day in dogs .

Properties of Bilastine

Melting point: 202 °C
Boiling point: 639.1±55.0 °C(Predicted)
Density  1.16±0.1 g/cm3(Predicted)
storage temp.  Sealed in dry,Room Temperature
Water Solubility  Insoluble in water
solubility  DMSO:49.3(Max Conc. mg/mL);106.34(Max Conc. mM)
form  powder to crystal
pka 4.40±0.10(Predicted)
color  White to Light yellow

Safety information for Bilastine

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
Precautionary Statement Codes P280:Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Bilastine

Abamectin manufacturer

SHOBHA LIFE SCIENCES PRIVATE LIMITED

1Y
Phone:+919121212469
Whatsapp: +91 9121212469
product: Bilastine 99%
Inquiry

Sekhment pharmaventures

1Y
Phone:+919030088669
Whatsapp: +91 9030088669
product: Bilastine 99%
Inquiry

Meenaakshi Molecules Pvt Ltd

1Y
Phone:+919121311126
Whatsapp: +91 9121311126
product: 202189-78-4 Bilastene 99%
Inquiry

Metrochem API Private Limited

1Y
Phone:+91-4069069999
product: Bilastine 98%
Inquiry

Viyash Life Sciences Pvt Ltd

1Y
Phone:+91-4023635052
product: Bilastine 98%
Inquiry

Aalidhra Pharmachem Pvt Ltd

1Y
Phone:+91-9879180894
Whatsapp: +91 9879180894
product: Bilastine 202189-78-4 98%
Inquiry

Lee Pharma Ltd

1Y
Phone:+91-9849085929
Whatsapp: +91 9849085929
product: 202189-78-4 Bilastine 98%
Inquiry

Integrin Life Sciences. Pvt. Ltd.

1Y
Phone:+91-9849990870
Whatsapp: +91-9849990870
product: 202189-78-4 99%
Inquiry

Centaur Pharmaceuticals Pvt Ltd

1Y
Phone:+912266499100
Whatsapp: +91 2266499100
product: Bilastine 99%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.